Delving into the Latest Updates on Hydroxyzine Hydrochloride with Synapse

Overview

Basic Info

SummaryHydroxyzine is a first-generation antihistamine that is commonly used for the treatment of various allergic conditions such as hives and itching. It works by blocking the action of histamine, a chemical released in response to an allergic reaction. Histamine causes symptoms such as itching, swelling, and rash. Hydroxyzine is available in oral and injectable formulations. It is generally well tolerated by patients. However, side effects can include drowsiness, dizziness and dry mouth. It is important to note that there is ongoing research regarding the potential use of hydroxyzine to treat anxiety disorders, as it has shown some anxiolytic activity in preclinical studies.

Drug Type

Small molecule drug

Synonyms

Hychotine, Hydroxine, Hydroxizine

+ [13]

Target

H1 receptor

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

UrticariaAnxiety DisordersDepressive Disorder+ [2]

Inactive Indication

Pruritus

Originator Organization

Pfizer Inc.

Active Organization

Pfizer Inc.

Shanghai Sine Pharmaceutical Co. Ltd.

Inactive Organization

Roerig SA

Drug Highest PhaseApproved

First Approval Date

US (12 Apr 1956),

Anxiety DisordersPruritusUrticaria

Regulation-

Login to view timeline

Structure

Molecular FormulaC21H29Cl3N2O2

InChIKeyANOMHKZSQFYSBR-UHFFFAOYSA-N

CAS Registry2192-20-3

The aim of this study is to evaluate the efficacy of hydroxyzine compared to treatment as usual (TAU) for patients with panic disorder. By conducting a pilot study, we hope to provide initial data on the feasibility and potential impact of hydroxyzine for this population. This will inform the design and power calculations of a larger, more comprehensive study in the future.
Objectives:
To assess the feasibility of conducting a randomized controlled trial (RCT) of hydroxyzine for panic disorder.
To evaluate the effectiveness of hydroxyzine compared to TAU in reducing panic symptoms in patients with panic disorder.
To explore the potential side effects and tolerability of hydroxyzine in this population.
Methods:
This will be a single-center, open-label, randomized pilot study. A total of 30 patients with a primary diagnosis of panic disorder will be recruited from a psychiatric outpatient clinic. Participants will be randomly assigned to receive either hydroxyzine or TAU for 8 weeks. The primary outcome measure will be the change in panic symptoms as assessed by the Panic Disorder Severity Scale (PDSS). Secondary outcome measures will include the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression-Severity (CGI-S) scale. Participants will be assessed at baseline, 4 weeks, and 8 weeks. Adverse events will be monitored throughout the study.
Expected Results:
This pilot study is expected to provide preliminary data on the feasibility and potential efficacy of hydroxyzine for panic disorder. The results will inform the design of a larger RCT to further evaluate the efficacy of hydroxyzine for this population.
Significance:
There is a need for effective and well-tolerated treatments for panic disorder. If found to be effective, hydroxyzine could provide a new option for patients with this condition, potentially improving their quality of life and functioning. The results of this pilot study will inform the design of future studies and contribute to the development of evidence-based treatments for panic disorder.

Start Date30 Dec 2023

Sponsor / Collaborator

University of Sultan Qaboos

NCT05680584 / RecruitingPhase 1IIT

Comparison Between the Effect of Oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in Pediatric Patients Undergoing Adenotonsillectomy

Comparison between the effect of oral Melatonin and Hydroxyzine for Preventing Preoperative Anxiety in pediatric Patients Undergoing Adenotonsillectomy

Start Date01 Feb 2023

Sponsor / Collaborator-

100 Clinical Results associated with Hydroxyzine Hydrochloride

Login to view more data

100 Translational Medicine associated with Hydroxyzine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Hydroxyzine Hydrochloride

Login to view more data

1,401

Literatures (Medical) associated with Hydroxyzine Hydrochloride

31 Dec 2024·ANNALS OF MEDICINE

Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis

Review

Author: Luo, Jie ; Zhang, Zhi-Xin ; Liu, Jia-Ling ; Huang, Cheng-Yang ; Yue, Li ; Zhang, Chao ; Zhao, Yi-Fan ; Liu, Run-Ben ; Li, Xiao-Zheng

OBJECTIVE:

The current guidelines and canonical norms of diagnosis or treatment for Post-traumatic stress disorder (PTSD) with sleep disorder are still conflicting and have not yet reached a consensus. This study aimed to unravel the most effective countermeasures between two categories (psychotherapy and pharmacotherapy) put forward by the National Institute for Health and Clinical Excellence (NICE) and World Federation of Societies of Biological Psychiatry (WFSBP) respectively to treat PTSD individuals co-exist with sleep disorders.

METHODS:

Four databases, including PubMed, EMBASE, Cochrane Library, and APA PsyNet, were searched from inception to February 02, 2023.

RESULTS:

Twenty articles with 24 Randomized controlled trials (RCTs) and a total number of 1,647 participants were included. As demonstrated in the network meta-analysis comparison results, CBT-I (standardized mean differences (SMD) = -1.51,95% confidence interval (CI):-2.55 to -0.47), CBT-I plus IRT (SMD = -1.71, 95%CI:-3.39, -0.03), prazosin (SMD = -0.87,95%CI:-1.59 to -0.16) and hydroxyzine (SMD = -1.06, 95%CI: -1.94 to -0.19) significantly reduced PTSD symptoms compared with placebo. In contrast to placebo, CBT-I (SMD = -5.61,95%CI:-8.82 to -2.40) significantly improved sleep quality. For nightmare severity, IRT (SMD =-0.65, 95%CI:-1.00 to -0.31), prazosin (SMD = -1.20,95%CI:-1.72 to -0.67) and hydroxyzine (SMD = -0.98,95%CI:-1.58 to -0.37) significantly reduced nightmare severity in comparison with placebo.

CONCLUSIONS:

This study suggested that under most circumstances, psychotherapy namely CBT-I had a favorable profile, but pharmacotherapy with prazosin was effective in managing nightmare severity. The sole avail of CBT-I was recommended to improving sleep quality while CBT-I and CBT-I plus IRT showed excellent management of PTSD symptom severity. Exposure to CBT-I isrecommended for depression. The relevant clinical guidelines for the management of individuals with PTSD and sleep disorders may regard this as a reference.

PROSPERO:

CRD42023415240.

01 Dec 2024·JOURNAL OF PALLIATIVE MEDICINE

Managing Pruritus in Advanced Chronic Disease

Review

Author: McDonald, Gord ; Kaya, Ebru ; Gallagher, Romayne

Even though pruritus affects a significant number of people with chronic disease, it is rarely adequately treated. Drug therapies often rely on antihistamines, which have not shown to be beneficial in systemic pruritus. Hydroxyzine is frequently used to treat pruritus associated with kidney failure. Since Canada's sole manufacturer of hydroxyzine is no longer making this product, this is an ideal time to review the mechanisms of itch in advanced organ failure and the specific therapies that give relief. Although there is literature describing itch in patients with cancer, this article is limited to pathogenesis and treatment of systemic itch secondary to chronic, noncancer diseases. We summarize recent systematic reviews, although the studies included in these reviews are often small, and mostly cohort studies.

01 Dec 2024·RADIOTHERAPY AND ONCOLOGY

Effects of dopamine receptor antagonists and radiation on mouse neural stem/progenitor cells

Article

Author: Pajonk, Frank ; Ioannidis, Angeliki ; He, Ling ; Bhat, Kruttika

BACKGROUND:

Dopamine receptor antagonists have recently been identified as potential anti-cancer agents in combination with radiation, and a first drug of this class is in clinical trials against pediatric glioma. Radiotherapy causes cognitive impairment primarily by eliminating neural stem/progenitor cells and subsequent loss of neurogenesis, along with inducing inflammation, vascular damage, and synaptic alterations. Here, we tested the combined effects of dopamine receptor antagonists and radiation on neural stem/progenitor cells.

METHODS:

Using transgenic mice that report the presence of neural stem/progenitor cells through Nestin promoter-driven expression of EGFP, the effects of dopamine receptor antagonists alone or in combination with radiation on neural stem/progenitor cells were assessed in sphere-formation assays, extreme limiting dilution assays, flow cytometry and real-time PCR in vitro and in vivo in both sexes.

RESULTS:

We report that hydroxyzine and trifluoperazine exhibited sex-dependent effects on murine newborn neural stem/progenitor cells in vitro. In contrast, amisulpride, nemonapride, and quetiapine, when combined with radiation, significantly increased the number of neural stem/progenitor cells in both sexes. In vivo, trifluoperazine showed sex-dependent effects on adult neural stem/progenitor cells, while amisulpride demonstrated significant effects in both sexes. Further, amisulpride increased sphere forming capacity and stem cell frequency in both sexes when compared to controls.

CONCLUSION:

We conclude that a therapeutic window for dopamine receptor antagonists in combination with radiation potentially exists, making it a novel combination therapy against glioblastoma. Normal tissue toxicity following this treatment scheme likely differs depending on age and sex and should be taken into consideration when designing clinical trials.

100 Deals associated with Hydroxyzine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00672	Hydroxyzine Hydrochloride	N05BB01	DB00557

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	JP	Pfizer Inc.	30 Sep 1965
Eczema	JP	Pfizer Inc.	30 Sep 1965
Nausea and vomiting	JP	Pfizer Inc.	30 Sep 1965
Anxiety Disorders	US	Pfizer Inc.	12 Apr 1956
Pruritus	US	Pfizer Inc.	12 Apr 1956
Urticaria	US	Pfizer Inc.	12 Apr 1956

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05126459 (CTgov)	Phase 3	Dental Caries	60	Meperidine+Hydroxyzine +Midazolam (Regimen 1)	pjovgmsapq(ptpswpewsf) = yvxanltobd dosleqtqsd (aueokehmbw, qzfzncfurj - geslcslkax) View more	-	02 Oct 2024
NCT05126459 (CTgov)	Phase 3	Dental Caries	60	Meperidine+Hydroxyzine (Regimen 2)	pjovgmsapq(ptpswpewsf) = vaozdwkzes dosleqtqsd (aueokehmbw, cjapnkauwt - eufkqlucri) View more	-	02 Oct 2024
NCT04068948 (CTgov)	Phase 4	Sedation \| Dental Caries	37	Meperidine+Hydroxyzine+Midazolam (Midazolam, Hydroxyzine, Meperidine)	fbkesfvxuy(augczyphis) = fcwcclsezb wopekjqcgy (gvcchxmbcs, ehfzeygbms - lqngfptjpe) View more	-	05 Dec 2023
NCT04068948 (CTgov)	Phase 4	Sedation \| Dental Caries	37	Hydroxyzine+Midazolam (Midazolam, Hydroxyzine)	fbkesfvxuy(augczyphis) = nwcplssqnx wopekjqcgy (gvcchxmbcs, hgaphekoqh - elohtwgdxc) View more	-	05 Dec 2023
NCT04188106 (HAVE, CTgov)	Phase 4	Nausea \| Dyssomnias \| Smoking Cessation	26	Varenicline Pill+Hydroxyzine Pill	nymzhuiqpo(oynhpgnwlo) = xflspxerrs uaxqhlskoi (eumdbaqbhu, dtnslouwio - akmizrjbrd) View more	-	03 Mar 2023
ASCO2005	Not Applicable	Ostealgia	-	G-CSF administration	ztxhmzjzgd(emccalazqk) = The bone pain frequently emerges as one of the side effects of G-CSF administration. Rising pressure within bone marrow by increased granulocytes, edema within bone marrow by histamine release, and increased level of bradykinin are thought to be the mechanisms underlying it. The incidence of bone pain is reported to be 1–5% of all cases, but in practice we have the impression that there have been more cases with bone pain, some of which are resistant to treatment with non-steroid anti-inflammatory drugs (NSAIDs). iyocnwvguk (nwhicygsfl )	-	01 Jun 2005